Inhibition of IGF-I–induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin  by Alric, Celine et al.
Kidney International, Vol. 62 (2002), pp. 412–421
Inhibition of IGF-I–induced Erk 1 and 2 activation and
mitogenesis in mesangial cells by bradykinin
CELINE ALRIC, CHRISTIANE PECHER, ERIC CELLIER, JOOST P. SCHANSTRA, BRUNO POIRIER,
JACQUES CHEVALIER, JEAN-LOUP BASCANDS, and JEAN-PIERRE GIROLAMI
INSERM U388, Institut Louis Bugnard, CHU Rangueil, Toulouse, and INSERM U430, Hoˆpital Broussais, Paris, France
Inhibition of IGF-I–induced Erk 1 and 2 activation and mito- leading to diabetic nephropathy. Insulin-like growth fac-
genesis in mesangial cells by bradykinin. tor-I (IGF-I) and to a lesser extent insulin, both induce
Background. The beneficial effects of therapeutic angioten- MC proliferation and collagen secretion most likely viasin-converting enzyme (ACE) inhibitor treatment against the
activation of the IGF-I receptor. Insulin thus may beworsening of glomerulosclerosis during the course of diabetic
involved in the early steps of the glomerulosclerotic pro-nephropathy have been widely documented. ACE inhibitors
inhibit both angiotensin II formation and bradykinin (BK) cess [1–4]. The renoprotective effect of angiotensin-con-
degradation, thereby reducing angiotensin II type 1 (AT1) verting enzyme (ACE) inhibitors on the progression of
receptor activity and favoring B2-kinin receptor (B2 receptor)
several renal diseases, including diabetic nephropathy,activation. Since the involvement of growth factors such as
is supported by a large number of reports [5–12]. Severalinsulin-like growth factor (IGF-I) has been implicated in the
early steps of diabetic nephropathy, we investigated the effect mechanisms were proposed to account for the beneficial
of BK on Erk 1 and 2 activation and cell proliferation by IGF-I. effects of ACE inhibitors. ACE inhibitors can inhibit the
Methods. The activation of Erk 1 and 2 in mesangial cells angiotensin II (Ang II)-induced increase in glomerular
(MCs) and isolated glomeruli (IG) was investigated by immu-
capillary resistance but also act on the Ang II-stimulatednoprecipitation and Western blotting during activation of the
secretion of matrix components by renal cells, indepen-IGF-I receptor in the presence or absence of BK and of protein
kinase C (PKC), tyrosine-kinase and phosphatase selective in- dently of any hemodynamic effects. Besides the Ang II-
hibitors. Mesangial cell proliferation was assessed in vitro by dependent mechanism, ACE inhibitors reduce the enzy-
cell counting. matic degradation of bradykinin (BK), thereby favoring
Results. In untreated MCs and IG, when added separately,
the stimulation of the B2 receptor (B2 receptor). ThisBK and IGF-I both activated Erk 1 and 2. In contrast, in MCs
is an additional potential mechanism in the protectiveand IG pretreated with BK, the IGF-I–induced Erk 1 and 2 ac-
tivation was dose-dependently reduced. The inhibitory effect of role of ACE inhibitor that has been poorly investigated.
BK on IGF-I–induced activation of Erk 1 and 2 was completely In order to document the role of Ang II in the develop-
abolished by addition of a B2 antagonist, by chelation of intra- ment of diabetic glomerulosclerosis, the combined ef-cellular calcium and by tyrosine phosphatase inhibition. Addi-
fects of Ang II and insulin on their signaling pathwaystionally, BK reduced MC proliferation induced by IGF-I.
has been investigated in mesangial cells (MCs) [13]. ItConclusions. A new inhibitory pathway of the early steps
of IGF-I signaling by the B2 receptor is found both in cultured was established that Ang II and insulin are additive in
MCs and in IG, which involves a calcium-dependent tyrosine stimulating the expression of transforming growth factor-
phosphatase activity. Recruitment of this mechanism may ac- beta (TGF-), a major prosclerotic cytokine up-regu-count for the beneficial effects of ACE inhibitor treatment on
lated by hyperglycemia. In contrast, possible cross-talkglomerulosclerosis associated with diabetic nephropathies.
between BK and insulin in the kidney has never been
investigated. In the past years, our group has docu-
Glomerular expansion during glomerulosclerosis re- mented in detail the presence of the BK receptors in the
sulting from mesangial cell (MC) hypertrophy and mes- kidney and in cultured MCs [reviewed in 14]. Initially,
angial matrix accumulation is believed to be a key event we observed that B2 receptor stimulation induced prolif-
eration of quiescent MCs [15], whereas our subsequent
study demonstrated that BK also was able to reduceKey words: insulin-like growth factor, diabetic nephropathy, MAP ki-
nase, tyrosine phosphatase, cell proliferation, glomerulosclerosis. MC proliferation induced by fetal calf serum (FCS) [16].
These opposite effects of BK have been confirmed by
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overexpressing the B2 receptor [20, 21]. More recently were lysed under stirring for 30 minutes in 1 mL of ice-
BK-induced inhibition of smooth muscle cell prolifera- cold lysis buffer [10 mmol/L Tris/HCl (pH 7.4 containing
tion was demonstrated; however, while this effect was 150 mmol/L NaCl, 1 mmol/L ethylenediaminetetraace-
independent of phospholipase C (PLC) and phospholi- tic acid (EDTA), 1 mmol/L egtazic acid (EGTA), 0.2
pase A2 (PLA2), the authors were not able to propose mmol/L orthovanadate, 1% NP 40 (vol/vol), 1% Triton
a more precise mechanism [22, 23]. X-100 (vol/vol), 0.2 mmol/L phenylmethylsulfonyl fluo-
We hypothesized that the effect of BK on cell prolifer- ride (PMSF), 1 g/mL leupeptin, 1 g/mL aprotinin]. In-
ation may be dependent upon growth factor receptor soluble material was removed by centrifugation at 13,000
activation. IGF-I is a peptide growth factor synthesized rpm for 20 minutes. Protein concentration was deter-
by many cells and tissues including MCs. An increase mined by the Bradford protein assay. Proteins of the sol-
in renal IGF-I levels has been implicated during the uble extract were boiled in Laemli buffer for five minutes
development of diabetic glomerulosclerosis by promot- at 100C and stored frozen until sodium dodecyl sulfate-
ing cell proliferation and collagen secretion [24–26]. In polyacrylamide gel electrophoresis (SDS-PAGE).
the present article, we extend the knowledge of the
mechanism of BK-induced activation of MAP kinase in Isolated glomerulus preparation
MCs in the absence and the presence of IGF-I. We found Freshly isolated glomeruli are the appropriate ex vivo
that BK alone induced a transient activation of Erk 1 preparation to extend the in vitro observations obtained
and 2, whereas it significantly reduced IGF-I-induced with cultured MCs to a more physiological environment.
Erk 1 and 2 activation, both in MCs and in IG. We Isolated glomeruli were prepared as routinely performed
propose a mechanism for this inhibitory cross-talk in- in the laboratory by graded sieving. Briefly, male Sprague-
volving a calcium-dependent tyrosine phosphatase. Fi- Dawley rats (12 weeks of age) were exsanguinated and
nally, we were able to demonstrate that BK reduced MC the kidneys were quickly removed. The cortex was forced
proliferation induced by IGF-I. through three consecutive steel sieves with decreasing
pore sizes (180, 125 and 75 m) and the glomeruli were
collected on the 75 m sieve. About 12,000 glomeruliMETHODS
per kidney were obtained. Under light microscopy, moreRat MC cultures
than 90% of the glomeruli appeared to be decapsulated
Mesangial cells were obtained as outgrowths of de- and free of surrounding tubules and arterioles. The glo-
capsulated collagenase-digested glomeruli obtained by meruli were resuspended in RPMI culture medium and
graded sieving as described previously [27]. Glomerular
redistributed in experimental tubes containing about
explants were allowed to grow to confluency at 37C
5000 glomeruli per tube. After the appropriate incuba-in a humidified atmosphere of 5% CO2 in RPMI 1640 tion time at 37C in the presence of various concentra-medium containing 15% FCS, 100 U/mL penicillin, 100
tions of BK and/or IGF-I, the incubation was stopped by
g/mL streptomycin and d-valine substituted for l-valine
adding 1 mL of ice-cold PBS containing 1 mmol/L of theto prevent fibroblast development. With this method,
tyrosine phosphatase inhibitor orthovanadate. Then theMCs appear in the culture after two to three weeks.
tubes were centrifuged (15,000 rpm, 4C, 2 min) andThey were characterized as previously described by mor-
the supernatant was discarded. The pellet containing thephological criteria, that is, the presence of multilayers,
glomeruli was resuspended in 100 L of lysis buffer,resistance to puromycin (10 g/mL), sensitivity to mito-
sonicated for 10 seconds and centrifuged (15,000 rpm,mycin (5 g/mL), presence of myosin filaments revealed
4C, 15 min). Insoluble material was removed and theby specific antibodies, presence of actin filaments re-
proteins of the soluble extracts were boiled in Laemlivealed by fluorescent NBD phallacidin, positive staining
buffer for five minutes and stored frozen until SDS-for the MC marker Thy-1.1, negative staining for the
PAGE. Protein concentration was determined by theendothelial cell marker factor VIII, and functional crite-
Bradford protein assay.ria such as an increase in intracellular calcium induced by
Ang II [27]. Experiments were performed with primary
SDS-PAGE and Western blottingcultures and passaged cells (passages 4 to 10).
Equal amounts of proteins (30 g) were separated by
Cell extract preparation 10% SDS-PAGE in Tris/glycine buffer under 150 volts
and 30 mA current in a Bio-Rad miniature gel apparatusConfluent cells were washed three times with serum-
(Mini-protean; Bio-Rad Laboratories, Richmond, CA,free culture medium and exposed to various agents in
USA). Proteins were then transferred to a nitrocelluloseserum-free culture medium at 37C. The reactions were
membrane (Amersham SA, Orsay, France). The mem-stopped by rapid aspiration of the medium and rinsing
brane was blotted with the appropriate antibody. Proteinsthree times with ice-cold phosphate-buffered saline
(PBS) containing 1 mmol/L sodium orthovanadate. Cells were visualized using a horseradish peroxidase-conjugated
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goat anti-rabbit immunoglobulin and an enhanced chemi- served five minutes after stimulation with 100 nmol/L
luminescence (ECL) kit (Amersham SA). BK (Fig. 1B). After 10 minutes of stimulation with BK,
Erk 1 and 2 phosphorylation returned to levels detected
Mitogen-activated protein kinase activity in the absence of BK. Total Erk 1 and 2 expression,
Mitogen-activated protein kinase activity was assessed studied with an antibody against phosphorylated and
by Western blotting using antiphospho-Erk antibodies non-phosphorylated forms of Erk, remained unchanged
(Promega, Madison, WI, USA), which recognize the ac- during stimulation with BK. In order to determine the
tive form of Erk 1 (MAP-kinase 1, molecular wt  44 receptor subtype involved in the BK-induced stimulation
kD) and Erk 2 (MAP kinase 2, molecular wt  42 kD). of Erk 1 and 2 phosphorylation, MCs were pretreated
The amount of total Erk also was visualized as a control with B1 and B2 antagonists, as shown in Figure 1C. The
using an antibody that recognizes total Erk 1 and 2 pro- B1 and B2 antagonists had no effect on Erk 1 and 2
teins (Santa Cruz Biotechnology, Le Perray, France) in- phosphorylation when given alone (Fig. 1C, lanes 15
dependently of their level of phosphorylation. In a pre- and 16). Pretreatment of MCs with 1 mol/L of the
liminary study, we established that in our experimental B2 antagonist HOE-140 (Fig. 1C, lane 14) but not with
conditions the detection of MAP kinase activity by this 1 mol/L of the B1 antagonist des-Arg9-Leu8-BK (Fig.
method was highly correlated with the incorporation of
1C, lane 17), completely abolished the BK-induced stim-
radioactive phosphorus in the myelin basic protein.
ulation of Erk 1 and 2 phosphorylation (Fig. 1C, lane 14
vs. lane 13).Proliferation studies
Mesangial cell proliferation was studied by counting Involvement of protein kinase C via a pertussis toxin-
the number of cells (Coulter cell counter ZM; Flow Lab- dependent signaling pathway in the BK-induced
oratory, Paris, France). MCs were seeded in 12-well phosphorylation of Erk 1 and 2
plates (Nunc; Polylabo, Strasbourg, France) at a density
When cells were pretreated for 24 hours with pertussisof 40,000 cells per well. After a 48-hour initial period in
toxin (PTX; 100 ng / mL), the stimulating effect of 100the presence of culture medium containing 15% FCS to
nmol/L BK on Erk 1 and 2 phosphorylation was inhibitedallow adhesion of the cells, they were rendered quiescent
(Fig. 2, lane 4 vs. lane 2) whereas PTX alone had noby 48 hours of serum deprivation in 0.5% FCS medium.
effect (Fig. 2, lane 3). In addition, the stimulating effectThen the effects of IGF-I in the presence and absence
of 100 nmol/L BK also was completely abolished by 10of BK were tested. The number of cells in triplicate
wells was determined after 48 or 72 hours as previously mol/L U73122, a phospholipase C (PLC) inhibitor (Fig.
described [15]. The results are expressed as absolute 2, lane 8 vs. lane 6). Next, we investigated the involve-
values  SEM. ment of protein kinase C (PKC; Fig. 3). A five-minute
treatment with 0.3 mol/L phorbol 12-myristate 13-ace-
Statistical analysis tate (PMA), resulting in translocation of isoforms , 
Results are expressed as mean  SEM. The t test for and ε but not  (data not shown), induced a 35-fold
unpaired data was used for comparisons between two increase in Erk 1 and 2 phosphorylation (Fig. 3A, lane
groups. For multiple comparisons, results were analyzed 1 vs. lane 3). In these conditions where PKC was highly
using a one-way analysis of variance (ANOVA) with a stimulated, no additional stimulation of Erk 1 and 2
Tukey-Kramer post-hoc test. Means were considered to phosphorylation was observed in response to stimulation
be significantly different when P 	 0.05. All analyses with 100 nmol/L BK for five minutes (Fig. 3A, lane 2
were performed with Statview 5 software (SAS Insti- vs. lane1). The stimulating effect observed after a five
tute Inc., Cary, NC, USA).
minute treatment with 100 nmol/L BK was prevented
by prior incubation with 5 mol/L PKC inhibitor GF
RESULTS 109203X (Fig. 3B, lane 7 vs. lane 5). Moreover, when
the MCs were pre-incubated for 18 hours with 0.3mol/LEffect of BK on Erk 1 and 2 phosphorylation in
PMA, a situation associated with complete down-regula-quiescent mesangial cells
tion of PKC (data not shown), the stimulating effect ofThe dose- and time-dependent effects of BK on the
BK on Erk 1 and 2 was no longer observed (Fig. 3C,phosphorylation of Erk 1 and 2 were studied by Western
lane 11 vs. lane 9). All these data indicate that Erk 1blot analysis (Fig. 1). Under our cell culture conditions,
and 2 phosphorylation can be directly triggered by acti-BK induced Erk 1 and 2 phosphorylation in a dose-
vation of PKC and that BK-induced Erk1 and 2 phos-dependent manner from 1 to 100 nmol/L, reaching a
phorylation is mediated via PLC and PKC recruitment.maximum stimulation of sixfold (Fig. 1A). The BK-
In all these experiments the total form of Erk 1 and 2induced stimulation of Erk 1 and 2 phosphorylation was
transient, and the maximum sixfold stimulation was ob- remained unchanged.
Alric et al: Cross-talk between bradykinin and IGF-I 415
Fig. 1. Dose- (A) and time-dependent (B) effect of bradykinin (BK) and pharmacological profile (C ) of BK activation of Erk 1 and 2 phosphoryla-
tion. Serum-depleted rat MCs were incubated: (A) for 5 min in the presence of increasing concentrations of BK (0 to 1000 nmol/L); (B) in the
presence of 100 nmol/L BK for different times (from 1 to 10 min); (C) in the presence of 100 nmol/L BK with either 1 mol/L of the B2 antagonist
HOE 140 (B2A) or 1 mol/L of the B1 antagonist des-Arg9-Leu8-BK (B1A). Erk 1 and 2 phosphorylation (P-Erk) was measured by Western
blotting with an antibody against the phosphorylated forms. Analyses were performed on an equal amount of protein (30 g) as measured with
an antibody against total-Erk (phosphorylated and non-phosphorylated forms). Erk 1 () and Erk 2 () phosphorylation (P-Erk 1 and 2) was
expressed by the fold increase of the ratio P-Erk versus total-Erk and is shown as mean  SE of the scanning densitometry of five experiments.
*P 	 0.05; **P 	 0.01 when compared to the level of P-Erk in the absence of BK. P 	 0.01 when compared to maximal P-Erk level detected
in MCs stimulated with 100 nmol/L BK (lane 13).
we evaluated the effects of two different tyrosine kinase
inhibitors: PD098059, an inhibitor of MEK1 (MAP ki-
nase kinase); and PPI, an inhibitor of the src protein
kinase family. Figure 4 shows that both 20 mol/L PPI
(Fig. 4, lanes 3 and 4) and 50 mol/L PD098059 (Fig. 4,
lanes 7 and 8) abolished the stimulating effect of BK,
indicating that a tyrosine kinase activity also is responsi-
ble for the action of the B2 receptor on MAP kinase
activation. The total forms of Erk 1 and 2 remained
unchanged in all experiments.
Effect of BK on Erk 1 and 2 activation in MCs
stimulated with IGF-I
Figure 5A demonstrates that IGF-I induced a dose-
dependent increase in Erk 1 and 2 phosphorylation in
FCS-free incubation medium. Moreover, when the ef-
Fig. 2. Effects of pertussis toxin (PTX) and phospholipase C inhibitor fects of IGF-I were compared with that of insulin (data(U73122) on BK-stimulated Erk 1 and 2 phosphorylation. Serum-
not shown), it appeared that both insulin and IGF-Idepleted rat MCs were incubated in the presence or absence of 100
nmol/L BK for 5 min and in the presence of PTX (lanes 3 and 4) or stimulated phosphorylation of Erk 1 and 2. However,
of 10 nmol/L U73122 (lanes 7 and 8). Western blotting was performed
IGF-I showed a much higher efficacy (10 nmol/L) thanas described in the legend of Fig. 1. Symbols are: () Erk 1; () Erk
2. N  5; *P 	 0.05, **P 	 0.01 when compared to the level of P-Erk in insulin (1 mol/L) confirming previous results indicating
the absence of BK. P 	 0.01 when compared to maximal P-Erk level that insulin probably acts through the stimulation of the
detected in MCs stimulated with 100 nmol/L BK (lanes 2 and 6).
IGF-I receptor in MCs [2, 3]. Interestingly, when MCs
were pretreated with 100 nmol/L BK for five minutes
BK-induced phosphorylation of Erk 1 and 2 requires prior to stimulation with 10 mol/L IGF-I, the maximum
tyrosine kinase activity IGF-I–induced stimulation of Erk 1 and 2 phosphoryla-
tion (Fig. 5B, lane 5) was significantly and dose-depen-To determine whether a tyrosine kinase activity was
involved in BK-induced Erk 1 and 2 phosphorylation, dently reduced to reach a 60  8% (P 	 0.05) maximum
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Fig. 3. Effects of protein kinase C stimulation
(A) and inhibition (B and C ) on BK-stimulated
Erk 1 and 2 phosphorylation. Serum-depleted rat
MCs were incubated: (A) in the presence or ab-
sence of 100 nmol/L BK for 5 min either in the
presence of PMA for 5 min (lanes 1 and 2); (B)
in the presence of GF109203, a PKC inhibitor
(lanes 6 and 7); and (C) after pretreatment with
PMA for 18 hours (lanes 10 and 11). Western
blotting was performed as described in the legend
of Fig. 1. Symbols are: () Erk 1; () Erk 2. N 
5, *P 	 0.05, **P 	 0.01 when compared to the
level of P-Erk in the absence of BK. P 	 0.01
when compared to maximal P-Erk level detected
in MCs stimulated with 100 nmol/L BK (lanes 5
and 9).
tase inhibitors. The inhibitory effect of 100 nmol/L BK
on 10 mol/L IGF-I-induced Erk 1 and 2 phosphoryla-
tion (Fig. 6; lane 3 vs. lane 2) was not altered by 100
mol/L okadoic acid, a serine-threonine phosphatase
inhibitor (Fig. 6, lane 5 vs. lane 3), okadoic acid alone
having no effect on the stimulation by 10 mol/L IGF-I
(Fig. 6, lane 4 vs. lane 2). In contrast, incubation in the
presence of the tyrosine phosphatase inhibitor orthovan-
adate significantly increased the levels of phosphorylated
Erk 1 and 2 (Fig. 6, lane 6 vs. lane 2) and interestingly
abolished the inhibitory effect of BK on IGF-I–induced
phosphorylation of Erk 1 and 2 (Fig. 6, lanes 7 and 8 vs.
lane 3). In addition, incubation in the presence of the
intracellular calcium chelator BAPTA/AM, increased
the level of P-Erk 1 and 2 after stimulation by IGF-I
Fig. 4. Effect of tyrosine kinase and src kinase inhibition on BK-stimu- (Fig. 6, lane 12 vs. lane 10), but also completely abolished
lated Erk 1 and 2 phosphorylation. Serum-depleted rat MCs were incu- the inhibition by BK of Erk 1 and 2 phosphorylationbated in the presence or absence of 100 nmol/L BK for 5 min and PPI,
(Fig. 6, lane 13 vs. 11). The specific effect of BK andan inhibitor of the src family protein (lanes 3 and 4) or PD090059, an
Erk 1 and 2 kinase (MEK) inhibitor (lanes 7 and 8). Western blotting BAPTA/AM on phosphorylated Erk 1 and 2 is demon-
was performed as described in the legend of Fig. 1. Symbols are: ()
strated by the unchanged levels of total Erk 1 and 2.Erk 1; () Erk 2. N  5, **P 	 0.01 when compared to the level of
P-Erk in the absence of BK. P 	 0.01 when compared to maximal
P-Erk level detected in MCs stimulated with 100 nmol/L BK (lanes 2 Effect of BK on IGF-I induced MC proliferation
and 6).
The effect of BK on MC proliferation is shown in
Figure 7. As expected in quiescent MCs, only a high
concentration of BK (1mol/L) induced a slight increase
reduction (Fig. 5B, lanes 6 to 8). This effect was pre- in MC proliferation (Fig. 7A). In MCs that were serum-
vented by B2 antagonist (Fig. 5C, lanes 10 to 12 vs. lanes
depleted to remove stimuli for cell proliferation, IGF-I7 and 8), which had no effect alone on IGF-I (Fig. 5C,
induced time- and dose-dependent MC proliferationlane 9). Moreover, the level of total Erk 1 and 2 remained
(not shown). The effect of BK was tested in the presenceunaffected.
of the peak IGF-I stimulation (10 nmol/L for 48 h). It
Involvement of a calcium-dependent can be shown that the IGF-I–induced stimulation of cell
tyrosine phosphatase proliferation was significantly and dose-dependently re-
duced in the presence of BK (1 nmol/L to 1 mol/L;As the decrease in Erk 1 and 2 phosphorylation sug-
Fig. 7 B). Moreover, no evidence of cell detachment orgests the activation of tyrosine phosphatase, we tested
the effect of both serine-threonine and tyrosine phospha- change in cell viability could be detected.
Alric et al: Cross-talk between bradykinin and IGF-I 417
Fig. 5. Effects of BK on IGF-I-stimulated
Erk 1 and 2 phosphorylation. Serum-depleted
rat MCs were incubated for 5 min: (A) in
the presence of increasing concentrations of
IGF-I from 0.1 to 10 nmol/L (lanes 2 to 4);
(B) in the presence of 10 nmol/L IGF-I and
increasing concentrations of BK from 0.1 to
10 nmol/L (lanes 6 to 8); (C ) in the presence
of 10 nmol/L IGF-I and increasing concentra-
tions of BK from 0.1 to 10 nmol/L and 1
mol/L of the B2 antagonist HOE 140 (lanes
9 to 12). Western blotting was performed as
described in the legend of Fig. 1. Symbols are:
() Erk 1; () Erk 2. N  5, *P	 0.05, **P	
0.01 P 	 0.01 when compared to the level of
P-Erk in the absence of BK (lane1). P 	
0.01 when compared to maximal P-Erk level
detected in MCs stimulated with 10 nmol/L
IGF-I (lane 5). 

P 	 0.01 when compared
to the level of P-Erk in the presence of IGF-I
and BK (lanes 7 and 8).
Fig. 6. Effects of orthovanadate, okadoic
acid and BAPTA/AM on BK-induced reduc-
tion of Erk 1 and 2 phosphorylation stimulated
with IGF-I. Serum-depleted rat MCs were in-
cubated in the presence or absence of IGF-I
for 5 min (lanes 2 to 8 and 10 to 13), 100
nmol/L BK (lanes 3, 5, 7,8, 11 and 13), okadoic
acid, an inhibitor of serine phosphatase (lanes
4 and 5), orthovanadate, an inhibitor of tyrosine
phosphatase (lanes 6 to 8), and BAPTA/AM,
a chelator of intracellular calcium (lanes 11
and 13). Western blotting was performed as
described in the legend of Fig. 1. N 5, **P	
0.01 when compared to the level of P-Erk in
the absence of BK. P	 0.01 when compared
to maximal P-Erk level detected in MCs stimu-
lated with 10 nmol/L IGF-I (lanes 2 and 4).


P 	 0.01 when compared to the level of
P-Erk in the presence of IGF-I and BK (lanes
3 and 11).
Effect of BK on IGF-I induced Erk 1 and 2 activation lowered IGF-I–induced Erk 1 and 2 phosphorylation
(Fig. 8D, lane 22 vs. 21) without any change in the levelin isolated glomeruli
of expression of the total forms of Erk 1 and 2. Finally,To extend the physiological significance of the inhibi-
the inhibitory effect of BK was absent in the presencetory effect of BK on Erk phosphorylation, we performed
of orthovanadate (Fig. 8D, lanes 25 and 26). These datasimilar experiments with freshly isolated rat glomeruli.
confirm that the BK-induced inhibition of Erk phosphor-As shown in Figure 8, when given alone, BK, IGF-I and
ylation promoted by IGF-I operates by a mechanisminsulin induced transient phosphorylation of Erk 1 and
found both in cultured MCs and in IG, indicating that2 that peaked at two minutes for BK (Fig. 8A, lane 3)
this inhibitory loop is physiologically relevant.
and between two and five minutes for IGF-I (Fig. 8B,
lanes 8 to 10) and insulin (Fig. 8C, lanes 14 to 16). How-
DISCUSSIONever, insulin concentrations higher than those of IGF-I
are required to induce similar Erk 1 and 2 phosphoryla- The rationale for this study was to test the hypothesis
of the involvement of BK as a possible negative modula-tion levels. In addition, as observed in cultured MCs, BK
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initial observation, the same group revised the mecha-
nism of GH-induced glomerulosclerosis and suggested
the involvement of both GH and IGF-I during low-pro-
tein-induced reduction of glomerulosclerosis [32]. The
same authors also reported that transgenic mice for GH
exhibited elevated plasmatic IGF-I concentrations asso-
ciated with glomerulosclerosis in spite of normal glyce-
mia [33]. Moreover, several studies have pointed out
that IGF-I acts as an initiation factor by inducing MC
proliferation [3, 34] and collagen secretion [4, 29, 35],
two major contributors to the development of diabetic
glomerulosclerosis, whereas similar direct effects of GH
on MCs have never been reported. Finally, inhibition of
early renal growth in diabetic and uninephrectomized
rats is prevented by the IGF-I antagonist [36]. All these
arguments support rather than detract from a contribu-
tion of IGF-I in diabetic nephropathies. Since MC hyper-
plasia is a feature common to several human glomerular
diseases, the inhibitory effect of BK on the signaling
cascade of IGF-I appears to be a potential protectiveFig. 7. Effects BK on MC proliferation. MCs were plated at a density
of 40,000 cells per well and were stimulated with increasing concentra- endogenous mechanism. This hypothesis is consistent
tions of BK for 48 hours in two different conditions. (A) MCs cultured with the renoprotective effects of ACE inhibitors ob-in RPMI medium containing 0.5% FCS. (B) MCs cultured in RPMI
served in experimental models and clinical trials as com-medium containing 10 nmol/L IGF-I. Cell proliferation is shown as
percent of control values obtained in the absence of BK and is expressed pared with other antihypertensive drugs [5–12].
as mean SE of five experiments. *P	 0.01, **P	 0.01 when compared Moreover, beside the effects on MC proliferation andto proliferation in the absence of BK.
matrix secretion, acute elevation of IGF-I by exogenous
administration reduces renal resistance and raises the
glomerular filtration rate at least in normal rats [37],
whereas the hemodynamic effects of chronic endogenoustor of IGF-I signaling pathways and IGF-I–stimulated
cell proliferation. Erk 1 and 2 activity is stimulated during elevation of IGF-I concentration remain controversial.
It also has been suggested that IGF-I–induced hyperfil-the early phases of hyperglycemia in diabetic rats [27]
and in MCs exposed to elevated glucose concentrations tration can be corrected by a B2-kinin antagonist [38].
However, that study was conducted for only 60 minutes[28]. The contribution of IGF-I–induced Erk 1 and 2
activation and cell proliferation is proposed as an essen- with exogenous infusion of high doses of IGF-I reaching
50 nmol/L. It is clear that in this acute situation IGF-Itial initial event in the development of diabetic nephrop-
athy. IGF-I is a growth factor locally released by MCs predominantly induced a vasodilatory effect. Blockade
of the B2 receptor can reduce this effect whereas thein the glomerulus during the development of diabetic
nephropathy and acts in an autocrine and paracrine fash- effect of chronic B2 blockade on the renal hemodynamics
of diabetic rats has never been reported. The variationsion [29]. Therefore, we tested the effect of BK on IGF-I–
induced Erk 1 and 2 activation. of the activity and expression of the kallikrein-kinin sys-
tem during diabetes mellitus expression have been inves-Although a BK-induced inhibition of fibroblast divi-
sion stimulated by a mixture of IGF-I and EGF has been tigated and show a biphasic pattern. During an acute
initial phase, glomerular hyperfiltration is prevented byreported [30], our study documents a possible mecha-
nism of an inhibitory effect of BK on IGF-I–induced Erk administration of a B2 antagonist. On the other hand,
renal kallikrein expression is suppressed in insulin-1 and 2 activation and cell proliferation. Interestingly, the
inhibitory effect of BK is not only observed in vitro in untreated streptozotocin (STZ)-diabetic rats and this
abnormality is reversed by insulin [39].cultured MCs, but also is detectable in a physiological
renal structure such as the isolated glomerulus. However, In order to associate the inhibition of MAP kinase
activation with a cellular response, we investigated the ef-the importance of IGF-I in the development of glomeru-
losclerosis of diabetic nephropathy could still appear fect of BK on IGF-I–induced MC proliferation. BK in-
hibits IGF-I–induced MC proliferation and this is consis-controversial. The main argument against a noxious ac-
tion of IGF-I in diabetes mellitus is the initial observation tent with the inhibition of Erk phosphorylation. Whereas
the proliferative action of BK on quiescent cell systemsshowing that transgenic mice overexpressing growth hor-
mone (GH) develop glomerulosclerosis whereas trans- has been extensively investigated, few studies report an
inhibitory effect of BK in smooth muscle cells, fibroblastsgenic mice overexpressing IGF-I do not [31]. Since that
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Fig. 8. Time-dependent effect of bradykinin (BK), IGF-I and insulin on Erk 1 and 2 phosphorylation in isolated glomeruli. Isolated glomeruli
were incubated in the presence of: (A) 100 nmol/L BK; (B) 65 nmol/L IGF-I; (C ) 1 mol/L insulin for increasing times from 0.5 to 20 min; (D)
in the presence of 65 nmol/L IGF-I, 100 nmol/L BK and orthovanadate (O-vanadate). Western blotting was performed as described in the legend
of Fig. 1. Symbols are: () Erk 1; () Erk 2. N  5, *P 	 0.05; **P 	 0.01 when compared to the level of P-Erk in the absence of growth factor.
P 	 0.01 when compared to maximal P-Erk level detected in glomeruli stimulated with 10 nmol/L IGF-I (lane 21). 

P 	 0.01 when compared
to the level of P-Erk in the presence of IGF-I and BK (lane 22).
or breast stromal cells [22, 23, 40, 41], and no mechanisms studies demonstrate the wide possibility of BK signaling
pathways mainly depending on the cell-types used. Withhave been proposed to date. The involvement of a tyro-
sine phosphatase in the reduction of MAP kinase activa- respect to MCs, it was first demonstrated by confocal
microscopy that BK caused nuclear translocation oftion therefore appears as a new finding with interesting
therapeutic perspectives. In this respect, the pharmaco- MAP kinase [18]. The pathway was only partly clarified
more recently, suggesting that the BK-stimulated MAPlogical inhibition of tyrosine kinase activity has demon-
strated therapeutic effectiveness in a well-characterized kinase pathway required only tyrosine phosphorylation,
thus appearing to be PKC independent [17]. The presentanimal model of polycystic kidney diseases resulting in
reduction of cystic lesions [42]. study provides a much more complete understanding of
the mechanism of MAP kinase activation by the endoge-In addition to the inhibitory effect of BK on IGF-I
signaling, the present article brings complementary data nous B2 receptor in rat MC primary culture. We demon-
strate that: (1) Erk 1 and 2 phosphorylation in MCs isconcerning the mechanism of stimulation of MAP kinase
by the B2 receptor. The pathways by which the B2 recep- strongly activated by PKC as revealed by the potent
effect of a five-minute exposure to PMA; (2) BK-inducedtor activates MAP kinase confirm a high degree of com-
plexity and cell specificity as previously reported for stimulation of Erk 1 and 2 was inhibited by inhibitors
of PKC, of PLC or of tyrosine kinase; (3) down-regula-other G-protein coupled receptors [43]. Using PC-12
cells transfected with dominant interfering mutants of tion of PKC by an 18-hour exposure to PMA resulted
in the absence of BK-induced stimulation of Erk 1 andPyk2, it was shown that BK-induced MAP kinase activity
resulted from an interaction between the proteins Pyk2 2 phosphorylation. From the present data it is now clear
that the activation of MAP kinase by the B2 receptor isand src [20]. The overexpression strategy used [20] is
not a favorable experimental condition to investigate only transient and is dependent on G-protein coupling
requiring both PKC and tyrosine kinase activity. Fromalternative signaling pathways as reported in the present
study. In rat aortic smooth muscle cells, BK stimulated our study in rat MCs, we can conclude that BK-induced
Erk 1 and 2 activation in MC requires both activationMAP kinase activity through a different pathway that
is insensitive to both pertussis and cholera toxins and of PKC and of proteins from the Src kinase family since
blockade of either of these two pathways resulted in theinvolves p60 Src kinase and PKC [19]. In the human
colon carcinoma cell line SW-40, a novel mitogenic sig- complete inhibition of BK-induced Erk 1 and 2 activa-
tion. In addition to this stimulating effect observed innaling pathway of BK has been reported and involves
sequential activation of a Gq/11 protein, phosphatidyl- quiescent cells, BK had an opposite antiproliferative ef-
fect in serum [16] or IGF-I–activated MCs. Accordinginositol 3-kinase , and PKC [21]. Taken together, these
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